Keymed Biosciences, Inc. (HK:2162) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keymed Biosciences Inc. has announced the approval of their new drug, Stapokibart, by China’s National Medical Products Administration for treating moderate-to-severe atopic dermatitis in adults. This first domestically manufactured IL-4R α antibody drug showed promising results in Phase III clinical trials, meeting primary endpoints and exhibiting a good safety profile. However, the company cautions shareholders that there’s no guarantee of successful commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.